DK2809683T3 - ANTI-phospholipase D 4 ANTIBODY - Google Patents

ANTI-phospholipase D 4 ANTIBODY Download PDF

Info

Publication number
DK2809683T3
DK2809683T3 DK13705843.4T DK13705843T DK2809683T3 DK 2809683 T3 DK2809683 T3 DK 2809683T3 DK 13705843 T DK13705843 T DK 13705843T DK 2809683 T3 DK2809683 T3 DK 2809683T3
Authority
DK
Denmark
Prior art keywords
sequence
antibody
pld4
ser
cell
Prior art date
Application number
DK13705843.4T
Other languages
Danish (da)
English (en)
Inventor
Minkwon Cho
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47748721&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2809683(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Application granted granted Critical
Publication of DK2809683T3 publication Critical patent/DK2809683T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK13705843.4T 2012-01-31 2013-01-31 ANTI-phospholipase D 4 ANTIBODY DK2809683T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012018266 2012-01-31
PCT/JP2013/052781 WO2013115410A2 (en) 2012-01-31 2013-01-31 Anti-phospholipase d4 antibody

Publications (1)

Publication Number Publication Date
DK2809683T3 true DK2809683T3 (en) 2018-12-10

Family

ID=47748721

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13705843.4T DK2809683T3 (en) 2012-01-31 2013-01-31 ANTI-phospholipase D 4 ANTIBODY
DK18188036.0T DK3431504T3 (da) 2012-01-31 2013-01-31 Antiphospholipase d4-antistof

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK18188036.0T DK3431504T3 (da) 2012-01-31 2013-01-31 Antiphospholipase d4-antistof

Country Status (15)

Country Link
US (2) US9944715B2 (enExample)
EP (2) EP2809683B1 (enExample)
JP (4) JP6118345B2 (enExample)
KR (1) KR102098413B1 (enExample)
CN (2) CN104284903B (enExample)
AU (2) AU2013215886B2 (enExample)
CA (1) CA2863009C (enExample)
DK (2) DK2809683T3 (enExample)
ES (2) ES2694165T3 (enExample)
HU (2) HUE054362T2 (enExample)
IL (1) IL233794B (enExample)
PL (2) PL2809683T3 (enExample)
PT (1) PT2809683T (enExample)
TR (1) TR201819828T4 (enExample)
WO (1) WO2013115410A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104284903B (zh) * 2012-01-31 2020-10-09 Sbi生物技术有限公司 抗磷脂酶d4抗体
PL3027656T3 (pl) * 2013-07-30 2019-10-31 Sbi Biotech Co Ltd Lek zawierający przeciwciało anty-fosfolipazowe D4
CN114292331A (zh) * 2013-12-24 2022-04-08 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
EP3402520A4 (en) * 2016-01-14 2019-01-02 BPS Bioscience, Inc. Anti-pd-1 antibodies and uses thereof
JP6979976B2 (ja) * 2016-03-10 2021-12-15 ヴィエラ バイオ，インコーポレーテッド Ｉｌｔ７結合分子及びその使用方法
CN105624325B (zh) * 2016-03-31 2019-06-11 北京泱深生物信息技术有限公司 肺腺癌的诊治标记物
BR112020007302B1 (pt) * 2017-10-14 2023-01-31 Abbvie Inc. Anticorpos ativáveis conjugados anti-cd71, método para fabrica-los, composição farmacêutica e kit que compreende os mesmos, usos dos ditos anticorpos, bem como método in vitro para detectar a presença ou ausência do agente de clivagem na amostra
CN110042123B (zh) * 2019-01-07 2023-01-17 西北农林科技大学 一种通过诱导表达zfp57提高牛体细胞克隆效率的方法
WO2025085746A1 (en) * 2023-10-18 2025-04-24 Immunorx Pharma Inc. Humanized anti-s100a9 antibody
CN119120388A (zh) * 2024-10-22 2024-12-13 江苏亲科生物研究中心有限公司 一种pdpfl单克隆抗体及其试剂盒的制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098015B2 (en) * 1999-06-11 2006-08-29 Millennium Pharmaceuticals, Inc. 27875, 22025, 27420, 17906, 16319, 55092 and 10218 molecules and uses therefor
EP1578947A4 (en) 2002-12-02 2006-12-06 Abgenix Inc ANTIBODIES TAKEN AGAINST PHOSPHOLIPASE A2 AND USES THEREOF
CA2544692C (en) * 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
CN104284903B (zh) * 2012-01-31 2020-10-09 Sbi生物技术有限公司 抗磷脂酶d4抗体
PL3027656T3 (pl) * 2013-07-30 2019-10-31 Sbi Biotech Co Ltd Lek zawierający przeciwciało anty-fosfolipazowe D4

Also Published As

Publication number Publication date
EP2809683B1 (en) 2018-10-03
EP3431504A1 (en) 2019-01-23
US20180258185A1 (en) 2018-09-13
IL233794A0 (en) 2014-09-30
AU2018200934A1 (en) 2018-03-01
AU2013215886A1 (en) 2014-08-14
JP6118345B2 (ja) 2017-04-19
KR102098413B1 (ko) 2020-04-07
TR201819828T4 (tr) 2019-01-21
EP3431504B1 (en) 2021-03-24
PL3431504T3 (pl) 2021-10-18
CN104284903B (zh) 2020-10-09
AU2018200934B2 (en) 2019-09-12
PL2809683T3 (pl) 2019-03-29
JP2019048874A (ja) 2019-03-28
CN104284903A (zh) 2015-01-14
WO2013115410A2 (en) 2013-08-08
US10336834B2 (en) 2019-07-02
KR20140126337A (ko) 2014-10-30
CA2863009A1 (en) 2013-08-08
WO2013115410A3 (en) 2013-09-26
ES2694165T3 (es) 2018-12-18
CN112442128A (zh) 2021-03-05
JP2021019630A (ja) 2021-02-18
HUE041552T2 (hu) 2019-05-28
EP2809683A2 (en) 2014-12-10
DK3431504T3 (da) 2021-06-28
IL233794B (en) 2021-04-29
CA2863009C (en) 2020-07-07
AU2013215886B2 (en) 2017-11-09
HUE054362T2 (hu) 2021-09-28
US9944715B2 (en) 2018-04-17
US20150044226A1 (en) 2015-02-12
BR112014018539A2 (enExample) 2017-06-20
BR112014018539A8 (pt) 2017-07-11
JP7244102B2 (ja) 2023-03-22
CN112442128B (zh) 2024-05-17
JP2015508056A (ja) 2015-03-16
JP2017155045A (ja) 2017-09-07
ES2873035T3 (es) 2021-11-03
PT2809683T (pt) 2019-01-17
JP6830471B2 (ja) 2021-02-17

Similar Documents

Publication Publication Date Title
KR102098413B1 (ko) 항-포스포리파아제 ｄ4 항체
JP6491701B2 (ja) 新規モジュレーターと使用の方法
HK1218126A1 (zh) 抗ilt7抗体
WO2012031273A9 (en) Novel modulators and methods of use
KR20140018837A (ko) 노텀 단백질 조절 인자 및 사용 방법
KR102367760B1 (ko) 항-포스포리파아제 d4 항체를 포함하는 의약
CN114450305A (zh) 抗cd137l抗体及其使用方法
Nishida et al. Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions
HK40039509A (en) Anti-phospholipase d4 antibody
HK40039509B (zh) 抗磷脂酶d4抗体
CN115403670B (zh) 抗cd40抗体及其用途
WO2026059649A1 (en) Jagged-1 binding agents and uses thereof
BR112014018539B1 (pt) Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide
HK1234068A1 (en) Novel modulators and methods of use
HK1234068A (en) Novel modulators and methods of use
HK1188797A (en) Anti-ilt7 antibody